A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

Blood

Volumn 112, Issue 5, 2008, Pages 1638-1645

  Faderl, Stefan ^a,b   Ravandi, Farhad ^a   Huang, Xuelin ^a   Garcia Manero, Guillermo ^a   Ferrajoli, Alessandra ^a   Estrov, Zeev ^a   Borthakur, Gautam ^a   Verstovsek, Srdan ^a   Thomas, Deborah A ^a   Kwari, Monica ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CYTARABINE; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERBILIRUBINEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHROMOSOME ABERRATION; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; GENETICS; MALE; MIDDLE AGED; MUTATION; SURVIVAL RATE;

ADENINE NUCLEOTIDES; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CHROMOSOME ABERRATIONS; CYTARABINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; SURVIVAL RATE;

EID: 52649154001     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-124602     Document Type: Article

References (22)

1. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107:3481-3485.
2. Estey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol. 2006;43:89-95.
3. Burnett AK. Mohite U. Treatment of older patients with acute myeloid leukemia-new agents. Semin Hematol. 2006:43:96-106.
4. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, et al. Synthesis and biologic activity of 2'tluoro-2-halo derivatives of 9-β-D- arabinofuranosyladenine. J Med Chem. 1992:35:397-401.
5. Parker WB, Allan PW. Hassan AE, et al. Antitumor activity of 2-tluoro-2'-deoxyadenosine against tumors that express Escherichia coii purine nucleoside phosphorylase. Cancer Gene Ther. 2003:10:23-29.
6. Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2' deoxyadenosine. Proc Natl Acad Sci U S A. 1992:89:2970-2974.
7. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2- tluoro-β-D-arabinofuranosyl)adenine in human lymphoblastoid cells. Cancer Res. 1995;55:2847-2852.
8. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-tluoro-β-D- arabinofuranosyl)adenine. Cancer Res. 1996;56:3030-3037.
9. Pui CH, Jeha S. Clotarabine. Nat Rev Drug Discov Suppl. 2005;S12-S3.
10. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clotarabine in patients with refractory or relapsed acute leukemia. Blood. 2003:102:2379-2386.
11. Faderl S, Gandhi V, O'Brien S, etal. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-G) in relapsed and refractory acute leukemias. Blood. 2005;105:940-947.
12. Faderl S, Verstovsek S, Gortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006;108: 48-51.
13. Burnett AK, Baccarani M, Johnson P, et al. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable [abstract]. Blood. 2006;108:130a. Abstract no. 425.
14. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114-1124.
15. Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. 2005:55:361-368.
16. Cheson BD, Bennett JM; Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria. Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21: 4642-4649.
17. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5:27-36.
18. Atallah E, Cortes J, O'Brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007;110:3547-3551.
19. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007;109:1387-1394.
20. Giles J. Rizzieri D, Karp J, et al. Cloretazine (VNP40101M) has significant activity as induction therapy for elderly patients with acute myeloid leukemia or advanced myelodysplastic syndrome. Haematologica. 2006;91(s1):43.
21. Ruter B, Knipp S, Germing U, Lübbert M. Cytogenetic responses in older patients with AMLand complex karyotype treated with low-dose 5-aza-2-deoxycytidin (decitabine). Haematologica. 2006;91(s1):44.
22. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with acute leukemia. Blood. 2006; 108:3271-3279.